指南与共识前列腺癌

EAU-EANM-ESTRO-ESUR-ISUP-SIOG前列腺癌指南2024更新第一部分:筛查、诊断与根治性局部治疗

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
指南 / 共识 · Eur Urol · 2024-04-13

该指南由EAU联合EANM、ESTRO、ESUR、ISUP、SIOG制定,基于2020年5月至2023年文献,对临床局限性前列腺癌的筛查、诊断和局部治疗提出推荐并标注推荐强度。推荐风险适应筛查、多参数磁共振成像避免不必要活检、靶向联合区域活检、PSMA PET成像分期、低危及部分有利中危患者主动监测,以及cN1患者局部治疗联合长期强化激素治疗。

要点

  • 推荐风险适应策略识别可能发生前列腺癌的男性,一般从50岁开始并结合个体化预期寿命。
  • 推荐使用多参数磁共振成像以避免不必要活检;活检时推荐靶向联合区域活检。
  • 低危及部分有利中危(ISUP分级组2)患者主动监测是适当处理;中危可考虑大分割放疗。

核心结论

  • 诊断、分期和局部治疗领域的证据快速演变,该指南体现前列腺癌管理的多学科性质。
  • 通过多步骤基于风险的筛查过程发现可治愈的前列腺癌,尽可能多地发现可治愈患者。
  • 局限性前列腺癌分为低危、中危、高危局限性和局部晚期,风险分层是治疗基础。

研究设计与样本

  • 由欧洲泌尿外科学会(EAU)、欧洲核医学协会(EANM)、欧洲放射肿瘤学会(ESTRO)、欧洲泌尿生殖放射学会(ESUR)、国际泌尿病理学会(ISUP)和国际老年肿瘤学会(SIOG)联合制定。
  • 专家组对2020年5月至2023年发表的英文新数据进行文献综述,更新指南并基于系统证据评价为每条推荐添加推荐强度。

主要发现

  • 建议采用风险适应策略识别可能发生前列腺癌的男性,一般从50岁开始并基于个体化预期寿命。
  • 推荐使用多参数磁共振成像以避免不必要活检;考虑活检时,应进行靶向联合区域活检。
  • 前列腺特异性膜抗原正电子发射断层成像(PSMA PET)是识别转移扩散最敏感的技术。
  • 主动监测是低危前列腺癌以及部分有利中危且国际泌尿病理学会(ISUP)分级组2患者适当的处理。
  • 对中危患者提供考虑大分割放疗的推荐;cN1前列腺癌患者应接受局部治疗联合长期强化激素治疗。

关键数值与推荐

  • 风险适应筛查策略一般从50岁开始,基于个体化预期寿命(原文未给出具体阈值或间隔)。
  • 低危前列腺癌及部分有利中危ISUP分级组2患者适合主动监测。
  • 中危患者考虑大分割放疗(推荐强度原文未在摘要中给出具体等级)。
  • cN1患者接受局部治疗联合长期强化激素治疗(推荐强度原文未在摘要中给出具体等级)。

临床怎么用

  • 采用风险适应策略识别可能发生前列腺癌的男性,一般从50岁开始并基于个体化预期寿命。
  • 使用多参数磁共振成像以避免不必要活检;活检时进行靶向联合区域活检。
  • PSMA PET成像用于识别转移扩散。
  • 低危及部分有利中危ISUP分级组2患者采用主动监测;低中危患者也应讨论主动监测作为选项。
  • 其他情况讨论手术或放疗等主动治疗及其潜在副作用,以实现共享决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines provide recommendations for the management of clinically localised prostate cancer (PCa). This paper aims to present a summary of the 2024 version of the EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on the screening, diagnosis, and treatment of clinically localised PCa. METHODS: The panel performed a literature review of all new data published in English, covering the time frame between May 2020 and 2023. The guidelines were updated, and a strength rating for each recommendation was added based on a systematic review of the evidence. KEY FINDINGS AND LIMITATIONS: A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is considered, a combination of targeted and regional biopsies should be performed. Prostate-specific membrane antigen positron emission tomography imaging is the most sensitive technique for identifying metastatic spread. Active surveillance is the appropriate management for men with low-risk PCa, as well as for selected favourable intermediate-risk patients with International Society of Urological Pathology grade group 2 lesions. Local therapies are addressed, as well as the management of persistent prostate-specific antigen after surgery. A recommendation to consider hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term intensified hormonal treatment. CONCLUSIONS AND CLINICAL IMPLICATIONS: The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. These PCa guidelines reflect the multidisciplinary nature of PCa management. PATIENT SUMMARY: This article is the summary of the guidelines for "curable" prostate cancer. Prostate cancer is "found" through a multistep risk-based screening process. The objective is to find as many men as possible with a curable cancer. Prostate cancer is curable if it resides in the prostate; it is then classified into low-, intermediary-, and high-risk localised and locally advanced prostate cancer. These risk classes are the basis of the treatments. Low-risk prostate cancer is treated with "active surveillance", a treatment with excellent prognosis. For low-intermediary-risk active surveillance should also be discussed as an option. In other cases, active treatments, surgery, or radiation treatment should be discussed along with the potential side effects to allow shared decision-making.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024. PMID: 38614820. doi:10.1016/j.eururo.2024.03.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。